Abstract
Canonical Wnt signaling has emerged as an important pathway that underlies the initiation of prostate cancer. Both human cancers and mouse models have confirmed that mutations or altered expression of components of this pathway are associated with prostate tumors. Additionally, several reports suggest that this pathway plays a key role in the establishment of skeletal metastasis. This review discusses our current knowledge of the Wnt signaling pathway in the development of prostate cancer. First, we will overview the Wnt signaling pathway to provide background for the rest of the discussion. We will then review the literature on the role of this pathway and the downstream effector, β-catenin, in the development and progression of prostate cancer and skeletal metastasis. We will also discuss reports that suggest that β-- catenin can directly interact with the androgen receptor to modulate its activity. These recent developments may provide insight into how tumor growth can be achieved under androgen deprivation. Finally, we speculate on how the pathway may be targeted for therapeutic treatment and what agents may be available to achieve this goal.
Current Drug Targets
Title: Wnt Signaling and Prostate Cancer
Volume: 9 Issue: 7
Author(s): Daniel R. Robinson, Cassandra R. Zylstra and Bart O. Williams
Affiliation:
Abstract: Canonical Wnt signaling has emerged as an important pathway that underlies the initiation of prostate cancer. Both human cancers and mouse models have confirmed that mutations or altered expression of components of this pathway are associated with prostate tumors. Additionally, several reports suggest that this pathway plays a key role in the establishment of skeletal metastasis. This review discusses our current knowledge of the Wnt signaling pathway in the development of prostate cancer. First, we will overview the Wnt signaling pathway to provide background for the rest of the discussion. We will then review the literature on the role of this pathway and the downstream effector, β-catenin, in the development and progression of prostate cancer and skeletal metastasis. We will also discuss reports that suggest that β-- catenin can directly interact with the androgen receptor to modulate its activity. These recent developments may provide insight into how tumor growth can be achieved under androgen deprivation. Finally, we speculate on how the pathway may be targeted for therapeutic treatment and what agents may be available to achieve this goal.
Export Options
About this article
Cite this article as:
Robinson R. Daniel, Zylstra R. Cassandra and Williams O. Bart, Wnt Signaling and Prostate Cancer, Current Drug Targets 2008; 9 (7) . https://dx.doi.org/10.2174/138945008784911831
DOI https://dx.doi.org/10.2174/138945008784911831 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry Current Perspectives in Prostate Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry One Pot Green Synthesis of Doxorubicin and Curcumin Loaded Magnetic Nanoparticles and Cytotoxicity Studies
Anti-Cancer Agents in Medicinal Chemistry Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Inhibitory Effects of Novel SphK2 Inhibitors on Migration of Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Polymers and Biopolymers as Drug Delivery Systems in Nanomedicine
Recent Patents on Nanomedicine Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry The Current Status of Cryotherapy and High-Intensity Focused UltraSound in the Treatment of Low-Grade Prostate Cancer
Reviews on Recent Clinical Trials The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry